Yes, we are a little bit late to the game, but the games not over, neither is the need.
We are a small biotech startup developing fast, better, simpler diagnostics for at-Home and Point-of-Care.
Our first 2 products are the first 4-min Covid Antigen Test called COVIDNOW-the fastest test on the market (preparing FDA EUA re-submission for May 2022). This is 2.5X faster than any other test on the market. Then we have the FAST-TEST for Pseudomonal Pneumonia (Prototype Ready).
QXD had filed seven total patents, with 5 being international for intellectual property protection, 1 Trademark application plus we have 3 patent applications for our COVIDNOW Technology.
We are cracking into an industry projected to grow to a $195 Billion dollar industry by 2027.
QXD Pipeline Includes:
1) COVIDNOW– a 4-minute Covid antigen test, Phone app, and AI technology.
-Resubmitting for FDA EUA approval this month.
-2-10M marketing capacity
-3 go-to-market strategies-We can be nationwide in 1000+Pharmacies w/i weeks of FDA EUA approval via our Physician 360 relationship
2) the FAST-TEST for Pseudomonal pneumonia – #1 and # 2 cause of ventilator and hospital-acquired antibiotic-resistant pneumonia that can result in death.
Prototype ready
3) BV/Candidiasis Test – BV & Candidiasis similar symptoms but with vastly different outcomes. BV increases risk/spread of HIV and impairs childbearing capability.
Design In-process
4) Exploring- Flu/Covid, Pneumonia Multiplex, Bronchitis, UTI, etc.
Total Previous Funding Raised-970K
Check us out on Wefunder and invest today for as little as $250
Thanks!
Check out our fundraiser on https://wefunder.com/quorum.x.diagnostics Invest today for as little as $250 dollars Closing in 2 weeks.
Yes, we are a little bit late to the game, but the games not over, neither is the need.
We are a small biotech startup developing fast, better, simpler diagnostics for at-Home and Point-of-Care.
Our first 2 products are the first 4-min Covid Antigen Test called COVIDNOW-the fastest test on the market (preparing FDA EUA re-submission for May 2022). This is 2.5X faster than any other test on the market. Then we have the FAST-TEST for Pseudomonal Pneumonia (Prototype Ready).
QXD had filed seven total patents, with 5 being international for intellectual property protection, 1 Trademark application plus we have 3 patent applications for our COVIDNOW Technology.
We are cracking into an industry projected to grow to a $195 Billion dollar industry by 2027.
QXD Pipeline Includes: 1) COVIDNOW– a 4-minute Covid antigen test, Phone app, and AI technology. -Resubmitting for FDA EUA approval this month. -2-10M marketing capacity -3 go-to-market strategies-We can be nationwide in 1000+Pharmacies w/i weeks of FDA EUA approval via our Physician 360 relationship
2) the FAST-TEST for Pseudomonal pneumonia – #1 and # 2 cause of ventilator and hospital-acquired antibiotic-resistant pneumonia that can result in death. Prototype ready
3) BV/Candidiasis Test – BV & Candidiasis similar symptoms but with vastly different outcomes. BV increases risk/spread of HIV and impairs childbearing capability. Design In-process
4) Exploring- Flu/Covid, Pneumonia Multiplex, Bronchitis, UTI, etc.
Total Previous Funding Raised-970K
Check us out on Wefunder and invest today for as little as $250 Thanks!